CFO
UTHR icon

Callan Family Office’s United Therapeutics UTHR Stock Holding History

Callan Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
2,246
+163
+8% +$91.8K 0.02% 546
2026
Q1 		$1.24M Sell
2,083
-189
-8% -$94.1K 0.03% 501
2025
Q4 		$1.11M Buy
2,272
+503
+28% +$234K 0.02% 520
2025
Q3 		$742K Sell
1,769
-1,699
-49% -$571K 0.02% 434
2025
Q2 		$997K Buy
3,468
+2,500
+258% +$747K 0.03% 404
2025
Q1 		$298K Buy
968
+50
+5% +$17.1K 0.02% 428
2024
Q4 		$324K Buy
+918
New +$337K 0.02% 465

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Callan Family Office's UTHR Position: Q2 2026 in Review

Callan Family Office increased its United Therapeutics (UTHR) stake by 7.8% in Q2 2026, buying an estimated $91.8K and bringing the position to 2,246 shares worth $1.22M. The position accounts for 0.02% of the portfolio, ranked #546.

Callan Family Office first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.24M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Callan Family Office held 2,246 shares of United Therapeutics worth $1.22M as of Q2 2026.
  • Callan Family Office bought 163 United Therapeutics shares in Q2 2026, an estimated $91.8K.
  • United Therapeutics made up 0.02% of Callan Family Office's portfolio in Q2 2026, its #546 holding.
  • Callan Family Office first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Callan Family Office's United Therapeutics position peaked at $1.24M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.